APOE and Alzheimer disease: Taken together, our findings indicate that increases in metabolites linked to oxidative DNA damage, changes in inhibitory neurotransmitters, disruptions of neuronal membranes, and decreases in metabolites related to acetylcholine synthesis drive the differences between early- and late-stage of AD among APOE ε3 carriers.